NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

计划入组 284 人 · 首次发布于 2025 年 8 月 5 日

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

计划入组 284 人 · 首次发布于 2025 年 5 月 8 日

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

计划入组 600 人 · 首次发布于 2025 年 8 月 11 日

NBI-355

NBI-1076986

NBI-1117570

NUI Galway

Ireland

Nabi Biopharmaceuticals

United States

NHI-1

United States

Neurocrine Launches Phase 1 Trial of Novel VMAT2 Inhibitor for Neurological Disorders

FDA Clears IND for Neurocrine and Nxera's Oral M1 Agonist NBI-1117567 in Alzheimer's Cognition

Neurocrine's NBI-1070770 Fails to Meet Primary Endpoint in Phase II Major Depressive Disorder Trial